Healthcare Regulation (HIPAA)

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

A new partnership between software specialist Cosylab and hardware innovator Heron aims to overcome the final hurdles in deploying a promising cancer therapy worldwide.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

A new partnership in regenerative medicine aims to capitalize on Florida's progressive laws. But does it signal a new era of healthspan or a risky medical frontier?

A new grand jury report exposes a perfect storm in SF jails: surging inmates with severe health needs, crumbling buildings, and burned-out staff.

Krisp launches Voice Translation v3 and a developer API, bringing its 96% accurate, battle-tested engine to high-stakes industries and innovators alike.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

ResVita Bio's new board member signals a major shift. We explore how visionary leadership and living medicine are converging to tackle long-neglected diseases.

As corporate giants swallow local clinics, one alliance offers a lifeline. Here’s how AllyGPO and BioCareSD use AI and service to help doctors stay independent.

EVERSANA poaches Takeda's Jen Norton to lead a new tech-first unit, signaling a high-stakes bid to dominate the complex life sciences access market.

With Bill S-228, Canada is criminalizing forced sterilization. It’s more than a new law; it’s a reckoning with a dark history and a test of reconciliation.

Dr. Farzad Mostashari’s recent accolade is more than an award; it’s a validation of a strategic model proving that realigning incentives can save billions.

Conexeu Sciences hits a key manufacturing milestone for its innovative wound-healing gel, but the path to FDA clearance and a crowded market remains a challenge.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.